来自癌症的外体阿鲁RNA促进结直肠癌的进展
Sara Magliacane Trotta1, Antonio Adinolfi1, Luca D'Orsi1,2
1Angiogenesis Lab, Institute of Genetics and Biophysics 'Adriano Buzzati-Traverso' - CNR, 80131, Naples, Italy.
Experimental & molecular medicine
|March 15, 2024
概括
阿鲁RNA激活NLRP3炎症酶,驱动结直肠癌的进展和转移. 外体阿卢RNA可能作为癌症诊断的新型非侵入性生物标志物.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 炎症是癌症进展的组成部分.
- 炎症酶,特别是NLRP3在癌症中的作用仍然不完全理解.
- 阿鲁RNA是一种内源核酸,已知可以激活NLRP3炎症酶.
研究的目的:
- 为了研究 Alu RNA 在结直肠癌 (CRC) 病变发生过程中的作用.
- 为了确定 Alu RNA 是否通过 NLRP3 炎症酶激活诱导表皮细胞转化为介质酶转化 (EMT).
- 探索外体ALURNA作为CRC的诊断生物标记物的潜力.
主要方法:
- 研究了Alu RNA对CRC细胞的影响,重点关注NLRP3炎症酶激活和IL-1β释放.
- 检查了外体在ALURNA运输到CRC细胞中的作用.
- 在患者数据和临床前模型中评估了Alu RNA表达/外体水平和CRC进展之间的相关性.
主要成果:
- 通过NLRP3炎症酶激活和IL-1β释放,ALU RNA在CRC细胞中诱导EMT.
- 外基因组调解了AluRNA的储存,运输和转移到CRC细胞,促进了入侵,转移和EMT.
- 增加的 Alu RNA 表达与人类 CRC 患者的 NLRP3 初始化相关.
- 在临床前模型中,循环外体阿鲁RNA水平与CRC进展相关.
结论:
- 阿鲁RNA通过激活NLRP3炎症酶直接促进结直肠癌的发病.
- 外体阿卢RNA在促进CRC瘤发生,侵袭和转移方面发挥着重要作用.
- 循环外体中的 Alu RNA 是一个有希望的非侵入性生物标志物,用于CRC诊断和进展监测.
更多相关视频
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
6.4K
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
13.7K
相关概念视频
02:07Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
02:39lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
02:21Cancers Originate from Somatic Mutations in a Single Cell
11.9K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
11.9K
03:18Non-LTR Retrotransposons
11.5K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.5K